PortalPublikationenAddition of AEG35156 XIAP antisense oligonucleotide in reind...

Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study.

Standard

Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. / Schimmer, Aaron D; Herr, Wolfgang; Hänel, Mathias; Borthakur, Gautham; Frankel, Arthur; Horst, Heinz-August; Martin, Sonja; Kassis, Jeannine; Desjardins, Pierre; Seiter, Karen; Fiedler, Walter; Noppeney, Richard; Giagounidis, Aristoteles; Jacob, Christine; Jolivet, Jacques; Tallman, Martin S; Koschmieder, Steffen.

in: CL LYMPH MYELOM LEUK, Jahrgang 11, Nr. 5, 5, 2011, S. 433-438.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schimmer, AD, Herr, W, Hänel, M, Borthakur, G, Frankel, A, Horst, H-A, Martin, S, Kassis, J, Desjardins, P, Seiter, K, Fiedler, W, Noppeney, R, Giagounidis, A, Jacob, C, Jolivet, J, Tallman, MS & Koschmieder, S 2011, 'Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study.', CL LYMPH MYELOM LEUK, Jg. 11, Nr. 5, 5, S. 433-438. <http://www.ncbi.nlm.nih.gov/pubmed/21729686?dopt=Citation>

APA

Schimmer, A. D., Herr, W., Hänel, M., Borthakur, G., Frankel, A., Horst, H-A., Martin, S., Kassis, J., Desjardins, P., Seiter, K., Fiedler, W., Noppeney, R., Giagounidis, A., Jacob, C., Jolivet, J., Tallman, M. S., & Koschmieder, S. (2011). Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. CL LYMPH MYELOM LEUK, 11(5), 433-438. [5]. http://www.ncbi.nlm.nih.gov/pubmed/21729686?dopt=Citation

Vancouver

Schimmer AD, Herr W, Hänel M, Borthakur G, Frankel A, Horst H-A et al. Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. CL LYMPH MYELOM LEUK. 2011;11(5):433-438. 5.

Bibtex

@article{0a69c058d1824301ac1105b8fcc7d1ad,
title = "Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study.",
abstract = "XIAP (X-linked inhibitor of apoptosis protein) is an inhibitor of caspases 3 and 9 that is overexpressed in acute myeloid leukemia (AML) and may contribute to chemoresistance. We report an open-label randomized phase II trial of reinduction chemotherapy with and without the XIAP antisense oligonucleotide AEG35156 in patients with AML who did not achieve remission with initial induction chemotherapy.",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Young Adult, Treatment Outcome, Remission Induction, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Leukemia, Myeloid, Acute/*drug therapy/genetics, Oligonucleotides/*administration & dosage, X-Linked Inhibitor of Apoptosis Protein/*antagonists & inhibitors/genetics, Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Young Adult, Treatment Outcome, Remission Induction, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Leukemia, Myeloid, Acute/*drug therapy/genetics, Oligonucleotides/*administration & dosage, X-Linked Inhibitor of Apoptosis Protein/*antagonists & inhibitors/genetics",
author = "Schimmer, {Aaron D} and Wolfgang Herr and Mathias H{\"a}nel and Gautham Borthakur and Arthur Frankel and Heinz-August Horst and Sonja Martin and Jeannine Kassis and Pierre Desjardins and Karen Seiter and Walter Fiedler and Richard Noppeney and Aristoteles Giagounidis and Christine Jacob and Jacques Jolivet and Tallman, {Martin S} and Steffen Koschmieder",
year = "2011",
language = "English",
volume = "11",
pages = "433--438",
journal = "CL LYMPH MYELOM LEUK",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "5",

}

RIS

TY - JOUR

T1 - Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study.

AU - Schimmer, Aaron D

AU - Herr, Wolfgang

AU - Hänel, Mathias

AU - Borthakur, Gautham

AU - Frankel, Arthur

AU - Horst, Heinz-August

AU - Martin, Sonja

AU - Kassis, Jeannine

AU - Desjardins, Pierre

AU - Seiter, Karen

AU - Fiedler, Walter

AU - Noppeney, Richard

AU - Giagounidis, Aristoteles

AU - Jacob, Christine

AU - Jolivet, Jacques

AU - Tallman, Martin S

AU - Koschmieder, Steffen

PY - 2011

Y1 - 2011

N2 - XIAP (X-linked inhibitor of apoptosis protein) is an inhibitor of caspases 3 and 9 that is overexpressed in acute myeloid leukemia (AML) and may contribute to chemoresistance. We report an open-label randomized phase II trial of reinduction chemotherapy with and without the XIAP antisense oligonucleotide AEG35156 in patients with AML who did not achieve remission with initial induction chemotherapy.

AB - XIAP (X-linked inhibitor of apoptosis protein) is an inhibitor of caspases 3 and 9 that is overexpressed in acute myeloid leukemia (AML) and may contribute to chemoresistance. We report an open-label randomized phase II trial of reinduction chemotherapy with and without the XIAP antisense oligonucleotide AEG35156 in patients with AML who did not achieve remission with initial induction chemotherapy.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Young Adult

KW - Treatment Outcome

KW - Remission Induction

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use

KW - Leukemia, Myeloid, Acute/drug therapy/genetics

KW - Oligonucleotides/administration & dosage

KW - X-Linked Inhibitor of Apoptosis Protein/antagonists & inhibitors/genetics

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Young Adult

KW - Treatment Outcome

KW - Remission Induction

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use

KW - Leukemia, Myeloid, Acute/drug therapy/genetics

KW - Oligonucleotides/administration & dosage

KW - X-Linked Inhibitor of Apoptosis Protein/antagonists & inhibitors/genetics

M3 - SCORING: Journal article

VL - 11

SP - 433

EP - 438

JO - CL LYMPH MYELOM LEUK

JF - CL LYMPH MYELOM LEUK

SN - 2152-2650

IS - 5

M1 - 5

ER -